Status unknownNCT03891498Updated Mar 27, 2019

The Effect of Loading Dose of Magnesium Sulfate on Uterine, Umbilical, and Fetal Middle Cerebral Arteries Doppler, Biophysical Profile, CTG, Maternal Vital Signs in Women With Severe Preeclampsia

An interventional study of MgSO4 in Preeclampsia, sponsored by Cairo University. Status unknown at 1 site in Egypt. Open to female participants aged 20 Years to 40 Years. Per ClinicalTrials.gov, last updated 2019-03-27.

Sponsored by Cairo University · Not applicable, Interventional, and Diagnostic

The sponsor has not verified this record recently (last verified Mar 2019), so the status shown — last known as Not yet recruiting — may be out of date.

Phase: Not applicable
Study type: Interventional
Enrollment: 100
Allocation: Not applicable
Ages: 20 Years to 40 Years
Sex: Female

Study summary

100 women with severe preeclanpsia received Magnesium sulfate 6 grams intravenous over 20 minutes as a loading dose. Resistance index [RI], pulsatility index [PI] and systolic/diastolic [S/D] ratio of the umbilical artery, uterine aryery and fetal middle cerebral artery before and repeated 20 minutes after intravenous administration of 6 grams of magnesium sulphate (loading dose) over 20 minutes . fetal breathing movements and fetal gross movements are counted within 20 minutes, before and after intravenous administration of 6 grams of magnesium sulphate (loading dose) over 20 minutes

Read the detailed description

Conditions studied

Preeclampsia

Browse trials for

Pre-Eclampsia 882

In context

Pre-Eclampsia

882 studies on the registry are indexed under Pre-Eclampsia; 237 are open to participants now.

This study's planned enrollment of 100 is close to the median of 110 across 468 interventional studies indexed under Pre-Eclampsia.

Browse Pre-Eclampsia studies →

Lead sponsor

Cairo University is the lead sponsor of 4,780 studies on the registry; 1,427 are open to participants now.

Of its 36 completed or terminated interventional studies of FDA-regulated products, 5 (14%) have results posted.

Counted across the registry records on this site, refreshed daily.

Who can participate

Ages eligible: 20 Years to 40 Years
Sexes eligible: Female
Accepts healthy volunteers: No

Inclusion criteria

Singleton pregnancy.
Primigravida or Multigravida.
Pregnant females ≥ 37 weeks of gestation.
Diagnosed as severe preeclampsia by the following criteria:
- Sustained systolic blood pressure of ≥160 mmHg or a sustained diastolic blood pressure of ≥ 110 mmHg.
- Proteinuria measured as +1 or more by dipstick or 24 hours urine collection with proteinuria ≥ 0.3 grams.
- Oliguria or creatinine > 1.1 mg%.
- Laboratory findings characteristic of HELLP syndrome.
- Symptoms suggestive of severe preeclampsia ; severe headache, blurring of vision, epigastric pain.

Exclusion criteria

Exclusion Criteria:

Multifetal pregnancy.
History of epilepsy.
Patients with diabetes.
Patients with renal disease.
Fetuses with congenital anomalies.
Patients receiving anticoagulants e.g. heparin (unfractionated or low molecular weight).
Patients with severe IUGR.
Patients with accidental hemorrhage.

Study design

Phase: Not applicable
Primary purpose: Diagnostic
Allocation: Not applicable
Intervention model: Single group
Masking: None (open label)
Enrollment: 100 participants (estimated)

Study arms

Experimental
MgSO4
The magnesium sulfate will be given according to the regimen of 6 grams intravenous over 20 minutes as a loading dose.
Drug: MgSO4

Interventions

DrugMgSO4
The magnesium sulfate will be given according to the regimen of 6 grams intravenous over 20 minutes as a loading dose.

What researchers measure

Primary outcomes

Changes in uterine artery resistance index
Doppler assessment of uterine artey RI
Time frame: 15 minutes after the loading dose of MgSO4

Study locations

1 site

Kasr Alainy medical school
Cairo, 12151, Egypt

Updates

Tracking since Sep 25, 2026

No changes since tracking began. The registry record was last updated on Mar 27, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗

Registry details

Key details

Study ID: NCT03891498
Lead sponsor: Cairo University
Responsible party: Ahmed M Maged, MD (Principal investigator, Cairo University) — Principal investigator
First posted: Mar 27, 2019
Start date: Mar 2019 (estimated)
Primary completion: Dec 2019 (estimated)
Completion: Dec 2019 (estimated)
Last update: Mar 27, 2019

Study contacts

Ahmed Maged, MD

Contact

prof.ahmedmaged@gmail.com

+201005227404

Mohamed Elmahy, MD

Contact

Mohamed.elmahy@kasralainy.edu.eg

01111831716

Ahmed Maged, MD

principal investigator · Professor

Oversight

Data monitoring committee: Yes
FDA-regulated drug: No
FDA-regulated device: No

View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Pre-Eclampsia→

Other studies from this sponsor

Cairo University

Start the discussion